Medical and Pharmaceutical Aerosols - Aerosols: Measurement, Dosimetry, and Health Effects - page 22

27. Rochat, T. and Morris, M.A. Gene therapy for cystic ibrosis by means of aerosol. Journal of Aerosol
Medicine 15 , 229-235 (2002).
28. Flotte, T. and Laube, B. Gene therapy in cystic ibrosis. Chest 120 , 124S-131S (2001).
29. Moss, R. et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic ibrosis transmem-
brane regulator gene transfer to the lungs of patients with cystic ibrosis—A multicenter, double-blind,
placebo-controlled trial. Chest 125 , 509-521 (2004).
30. Tang, L. et al. RASONs: A novel antisense oligonucleotide therapeutic approach for asthma. Expert
Opinion on Biological Therapy 1 , 979-983 (2001).
31. Jiang, H. et al. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-
polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials 30 , 5844-
5852 (2009).
32. Xu, C. et al. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung
tumorigenesis. American Journal of Respiratory and Critical Care Medicine 178 , 60-73 (2008).
33. Devuni, D. and Wu, G. ALN-RSV01 siRNA targeting RSV nucleocapsid N gene treatment of RSV infec-
tion. Drugs of the Future 34 , 781-783 (2009).
34. DeVincenzo, J. RNA interference strategies as therapy for respiratory viral infections. Pediatric Infectious
Disease Journal 27 , S118-S122 (2008).
35. BPC British Pharmaceutical Codex, ed., The Pharmaceutical Press, London, (1973).
36. Lechuga-Ballesteros, D. et al. Trileucine improves aerosol performance and stability of spray-dried
powders for inhalation. Journal of Pharmaceutical Sciences 97 , 287-302 (2008).
37. Byron, P.R. and Patton, J.S. Drug delivery via the respiratory tract. Journal of Aerosol Medicine 7 , 49-75
(1994).
38. Bitonti, A.J. et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates
through an immunoglobulin transport pathway. Proceedings of the National Academy of Sciences of the
United States of America 101 , 9763-9768 (2004).
39. Wylam, M.E. et al. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar
proteinosis. European Respiratory Journal 27 , 585-593 (2006).
40. Spyker, D., Munzar, P., and Cassella, J. Pharmacokinetics of loxapine following inhalation of a thermally
generated aerosol in healthy volunteers. Journal of Clinical Pharmacology 50 , 169-179 (2010).
41. Anon. Staccato goes to FDA for review. Journal of Psychosocial Nursing and Mental Health Services
48 , 47-47 (2010).
42. Siekmeier, R. and Scheuch, G. Systemic treatment by inhalation of macromolecules—Principles, prob-
lems, and examples. Journal of Physiology and Pharmacology 59 , 53-79 (2008).
43. Siekmeier, R. and Scheuch, G. Treatment of systemic diseases by inhalation of biomolecule aerosols.
Journal of Physiology and Pharmacology 60 , 15-26 (2009).
44. Omer, S., Hiremath, G., and Halsey, N. Respiratory administration of measles vaccine. Lancet 375 ,
706-708 (2010).
45. Burger, J. et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine.
Journal of Aerosol Medicine and Pulmonary Drug Delivery 21 , 25-34 (2008).
46. Shi, S. and Hickey, A. PLGA microparticles in respirable sizes enhance an in vitro T cell response
to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B. Pharmaceutical Research 27 ,
350-360 (2010).
47. Corbett, M. et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and
immunogenic. Proceedings of the National Academy of Sciences of the United States of America 105 ,
2046-2051 (2008).
48. Hunter, Z., Smyth, H.D., Durfee, P., and Chackerian, B. Induction of mucosal and systemic antibody
responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a
virus-like particle based vaccine. Vaccine 28 , 403-414 (2009).
49. Im, E. et al. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human
immunodeiciency virus type 1 through breastfeeding. Journal of Virology 81 , 9408-9418 (2007).
50. DiNapoli, J. et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuramini-
dase protein of H5N1 highly pathogenic avian inluenza virus protect against virus challenge in monkeys.
Journal of Virology 84 , 1489-1503 (2010).
51. Orson, F. et al. Protection against inluenza infection by cytokine-enhanced aerosol genetic immuniza-
tion. Journal of Gene Medicine 8 , 488-497 (2006).
52. Giudice, E. and Campbell, J. Needle-free vaccine delivery. Advanced Drug Delivery Reviews 58 , 68-89
(2006).